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ABSTRACT
Thrombocyte concentrate (TC) transfusion is an important supportive therapy in patients 
with thrombocytopenia. The risks in platelet transfusions may be related to the content of 
TC including the contaminant leukocytes. The aim of this study was to assess the risk of 
increased level of P-Selectin (CD62P) expression of non-leukodepleted TC transfusions.
This was a quasi-experimental study. Subjects were children patients aged 1-18 years 
who received a non-leukodepleted or a leukodepleted TC transfusions. Comparison of the 
proportion of increased expression of CD62P in both groups expressed as relative risk. 
The subjects consisted of 51 patients who received non-leukodepleted and 52 patients 
who received leukodepleted TC transfusions. The risk of increased expression of CD62P in 
patients receiving non-leukodepleted TC transfusions were 2.38 (95%CI:1.60-3.53) times 
higher than those who received leukodepleted TC. Non-leukodepleted have significant 
higher risks of increased CD62P expression than leukodepleted TC transfusions. 
ABSTRAK
Transfusi thrombocyte concentrate (TC) merupakan terapi pendukung yang penting 
pada pasien yang mengalami trombositopenia. Risiko yang terjadi dapat terkait dengan 
komponen yang terkandung dalam TC termasuk adanya lekosit kontaminan. Penelitian ini 
bertujuan untuk menilai risiko berupa kejadian peningkatan ekspresi P-selectin (CD62P) 
pada transfusi TC non-lekodeplesi. Penelitian ini merupakan penelitian eksperimental 
semu. Subjek penelitian adalah pasien anak usia 1-18 tahun yang mendapat transfusi 
TC non-lekodeplesi dan lekodeplesi. Perbandingan proporsi peningkatan ekspresi CD62P 
pada kedua kelompok dinyatakan dalam risiko relatif. Subjek terdiri dari 51 pasien yang 
mendapatkan transfusi TC non-lekodeplesi dan 52 pasien yang mendapatkan transfusi TC 
lekodeplesi. Risiko peningkatan ekspresi CD62P pada pasien yang mendapatkan transfusi 
TC non-lekodeplesi adalah 2,38 (95%CI:1,60-3,53) kali lebih tinggi dibandingkan yang 
mendapatkan transfusi TC lekodeplesi. Transfusi TC non-lekodeplesi memiliki risiko yang 
lebih tinggi bermakna dibandingkan TC lekodeplesi.
Keywords: thrombocyte concentrate – transfusion – CD62P expression - 
thrombocytopenia – adverse effect
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INTRODUCTION 
Globally, total blood donations are 
approximately 107 million units annually, 
which is almost fifty percents collected in 
high-income countries. In Indonesia 4,644,863 
units of blood products were processed in 
2014, which were consisted of 16.18% whole 
blood and 83.82% components. From those 
components, 58% were packed red cells 
(PRC), 22% were fresh plasma, 13% were 
thrombocyte concentrate (TC), 6% were fresh 
frozen plasma (FFP), 0.18% were washed 
erythrocyte, 0.65% were cryoprecipitate, and 
0.17% were apheresis platelet.1 At Dr. Sardjito 
General Hospital, Yogyakarta, approximately 
36,000 units of blood components transfusion 
are registered annually. The increase of TC 
use has been noted from 29.52% in 2011 to 
37.2% in 2015. Pediatry ward was the largest 
TC user, and there has been a steady increased 
of TC use from 51.20% in 2011 to 67.01% in 
2015.2
Platelet transfusion is associated with 
post-transfusion reaction including allergic 
reaction and febrile non-hemolytic reaction.3 
To reduce the risk of leukocyte-associated 
transfusion adverse event, blood component 
should be leukoreduced before usage.4 So 
far, there is little concern about leukocyte 
contaminants within blood component 
especially in developing countries. One 
of many methods described to eliminate 
thrombocyte transfusion reaction is by doing 
TC leukodepletion. Leukodepletion is a 
procedure to remove leukocyte contaminants 
present within blood component, using a 
specific filter.5
Nielsen et al.6 reported accumulation of 
chemical mediators as the result of leukocyte 
intracellular granule release during blood 
component storage (PRC or TC) such as 
histamine, eosinophil cationic protein, 
eosinophil protein X, myeloperoxidase, and 
plasminogen activator inhibitor-1. Leukocyte 
could affect the function of platelets by 
releasing any chemical substances for example 
cathepsin G, reactive oxygen species, nitric 
oxide,7,8 and myeloperoxidase (MPO).6
Myeloperoxidase is originally an enzyme 
stored inside the granule of polymorphonuclear 
cell (PMN), its detectable level in circulation 
reflects the degranulation of PMN and PMN 
cells that undergo necrosis during blood 
component storage also produce it. This enzyme 
is secreted along with other biochemical 
substances like protease and peroxydase to 
surrounding extracellular environtment.9 
MPO-induced platelet activation is marked by 
increasing expression of P-selectin (CD62P) 
and Platelet Endothelial Cell Adhesion 
Molecule-1(PECAM-1).10-12 This study was 
aimed to compare the CD62P expression in 
patients receiving non-leukodepleted versus 
leukodepleted thrombocyte concentrates.
MATERIALS AND METHODS 
Subjects
Study subjects of this research were 
pediatric patients receiving transfusion of 
either non-leukodepleted or leukodepleted TC 
during their care in Estella ward Dr. Sardjito 
General Hospital, Yogyakarta. The subjects 
were selected in consecutive sampling basis 
according to inclusion and exclusion criteria. 
Randomization could not be performed 
properly because of a limitation in preparing 
leukodepleted TCs. Inclusion criteria of this 
study were all pediatric patient age 1-18 
years old diagnosed with malignancy and 
indicated to receive platelet transfusion. 
The study subjects would be excluded from 
research if he had bleeding manifestation, 
DIC, hypersplenisms, fever, receiving 
antipiretic or antithrombotic therapy or other 
blood component transfusions. Study subjects 
were categorized into two groups, first group 
received non-leukodepleted TC and another 
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grup received leukodepleted TC transfusion. 
Protocol of this study has been approved 
by the Medical and Health Research Ethics 
Committee of Faculty of Medicine, Univesitas 
Gadjah Mada, Yogyakarta. Leukodepleted 
thrombocyte concentrates were platelet-
pooled (2-4 units) derived from whole blood 
with CPDA1 processed using PRP method 
and filtered to remove leukocyte contaminants 
before stored in agitator at 20 – 24 ᴼC 
for maximum 5 days. Non-leukodepleted 
thrombocyte concentrates were produced 
using the same process without undergone 
leukocyte filtration. 
Measurement of CD62P expression using 
flowcytometry method
The method applied in this research 
refered to previous method developed by 
Kim and Lim,13 which minimalize platelet 
activation artificially, eliminating the need of 
centrifugation for washing and fixation before 
labelling and simultaneously label monoclonal 
antibody to the patient platelets. CD62P 
expression was measured by flowcytometry 
method using monoclonal antibody anti-
CD62P-FITC against whole blood sample 
without addition of agonist (ADP). The 
measurement was conducted on blood sample 
before and 1 hour after TC transfusion (pre 
vs. post-transfusion). For analytical purpose, 
gates were made in predetermined platelet 
area with addition of anti-CD41-PE (FIGURE 
1). Data were presented as platelet percentage 
that positively expressed CD62P.
FIGURE 1. Dot plot and statistic quadrans of CD62P measurement
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Data analysis
Subject characteristics was presented 
descriptively. The percentage of platelet (%) 
that expressed CD62P was presented as mean 
value. The comparison of increased CD62P 
expression in both groups was presented 
as relative risk. Statistical analysis was 
performed at significance value p < 0.05 with 
confidence interval of 95%.
RESULTS
Total subjects enrolled in this study 
were 103 patients, divided into 2 groups; 
first group consist of 51 patients receiving 
non-leukodepleted TC and another group 
of 52 patients receiving leukodepleted TC 
transfusion. Subject characteristics were 
summarized in TABLE 1. Overall, there were 
no statistically significant difference (p >0.05) 
between two groups in term of gender, age, 
body weight, height, body surface area (BSA) 
and body mass index (BMI).
TABLE 1. Characteristics of subjects 
Characteristic
Non-leukodepleted 
(n=51)
Leukodepleted 
(n=52) p
Gender
Male 32 (62.7%) 30 (57.7%) 0.600
Female 19 (37.3%) 22 (42.3%)
Age (mean ± SD year) 8.69 ± 4.83 9.93 ± 5.10 0.209
1-5 16 12
5-10 17 17
10-14 7 6
14-18 11 17
Weight (mean ± SD kg) 26.12 ± 15.84 26.67 ± 12.84 0.847
Height (mean ± SD m) 1.22 ± 0.28 1.28 ± 0.29 0.279
BSA (mean ± SD m2) 0.925 ± 0.379 0.975 ± 0.354 0.491
BMI (mean ± SD kg/m2) 16.048 ± 4.10 15.279 ± 2.64 0.259
In this study, CD62P expression on platelet 
was measured from patient venous blood 
sample before and 1 hour after TC transfusions. 
Mean expression of CD62P before transfusion 
was not statistically significant difference 
between two groups i.e. 25.42 ± 19.52% in 
non-leukodepleted group and 27.16 ± 10.31% 
in leukodepleted group respectively (p > 
0.05). On the contrary, there was statistically 
significant difference in mean expression 
of post-transfusion CD62P (p < 0.05), wich 
the group receiving non-leukodepleted TC 
expressed higher level (35.85 ± 20.31%) 
than the group receiving leukodepleted TC 
transfusion (24.12 ± 7.16%). Mean expression 
of post-transfusion CD62P in group receiving 
non-leukodepleted TC post- transfusion was 
increased than pre-transfusion, meanwhile in 
leukodepleted group, it was slightly decreased 
as seen in TABLE 2.
125
Triyono et al., Comparing P-Selectin (CD62P) expression in patients receiving
non-leukodepleted versus leukodepleted thrombocyte concentrates
TABLE 2. Mean expression of pre and post-transfusion CD62P
Group
Non-leukodepleted
(n = 51)
%
Leukodepleted
(n = 52)
%
p
Pre-transfusion 25.42±19.52 27.16±10.31 0.574
Post-transfusion 35.85±20.31 24.12±7.16 0.000
Relative risk of increased CD62P 
expression in patients receiving non-
leukodepleted TC compared to leukodepleted 
group was presented in the TALE 3. It was 
seen that the increased CD62P expression 
was 2.38 times higher in the group receiving 
non-leukodepleted TC than leukodepleted TC 
transfusions.
TABLE 3. Relative risk of increased CD62P expression in non-leukodepleted group
Group Increment (+) Increment (-) Total p
Non-leukodepleted 42 9 51
Leukodepleted 18 34 52 0.000
Total 60 43 103
Relative risk = 2.38; (95%CI=1.60-3.53)
DISCUSSION 
The increased expression of post-
transfusion CD62P was greater in the 
group receiving non-leukodepleted TC 
than leukodepleted TC probably caused by 
addition effects of pretransfusion activated 
donor platelets or the effect of increased level 
of MPO in transfused TCs. Nomura et al.14 
have conducted a research with transfusion 
of 100 TCs involved 28 hematologic and 
non-hematologic malignancy patients, it was 
concluded that platelet CD62P expression 
was diminished significantly after leukocyte 
filtration process or leukodepletion. 
There were some markers to evaluate 
platelet activation such as β-Thyroglobulin (β-
TG), Glycoprotein-1β (GPIB/CD42), platelet 
aggregation test or GPIIb/IIIa (CD41), soluble 
P–selectin, surface P-selectin (CD62P), and 
among them CD62P is the best marker.15-17 
CD62P also known as α-granule platelet 
membran protein-140 (GMP-140), expressed 
on the surface membrane during platelet 
activation, but remain undetectable in resting 
platelets. CD62P reported to be expressed 
rapidly on the surface membrane when platelet 
is activated.18 CD62P is the most sensitive and 
specific marker which reflects activation of 
platelets. Among other activated thrombocyte 
surface marker, CD62P expression shows the 
most significant difference between activated 
and resting platelet state.18,19
There was a correlation between 
P-selectin expression and platelet survival 
after transfusion, stronger expression of 
P-Selectin on the platelet surface, associated 
with easier destruction of platelet after being 
transfused.18,19 After activation, platelets will 
release proinflammatory chemokine, cytokine 
and adhesion molecule appear onto its surface, 
including CD62P and CD40 ligand (CD40L). 
Interaction between platelet and neutrophyl 
triggers recruitment of neutrophyles to the 
inflammed tissue, activates the neutrophyles 
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and it contribute toward host immunity 
and thrombosis process. Human neutrophil 
α-defensins (HNPs) consist of 50% protein 
from azurophilic granules. It can be released 
from azurophilic granule into extracellular 
environtment after PMN cell activation and 
then undergo degranulation, leakage, cell 
death and lysis during inflammation.20
Clinical relevance of CD62P expression 
level to predict in vivo platelet behaviour 
after transfusion is still debatable and not 
fully understood. It is partly based on fact 
that dynamicity of platelet and loss of CD62P 
surface protein.21 There was evidence that 
P-selectin level increased during storage, 
whereas its activatability undergo reduction.22 
Increased level of CD62P significantly 
unrelated to body mass index (BSA), carotid 
intima media thickness and inflammatory 
mediator (CRP).17
CONCLUSION
In conclusion, non-leukodepleted have 
significant 2.38 times higher risk of increased 
post-transfusion CD62P expression than 
leukodepleted TC transfusions.
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